CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026

Phase 1JBI-802
Related Companies

Read the original article

Published by PR Newswire Biotech on September 15, 2026 1:32 PM

Read Original